Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia
International Urology and Nephrology · 2023
DOI: 10.1007/s11255-023-03476-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2023. Verfasst von Jae Duck Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Kor…. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To assess adherence to combination therapy comprising α-adrenergic blocker (AB) and 5α-reductase inhibitor (5ARI) for benign prostatic hyperplasia (BPH) in a real-world setting and whether lower urinary tract symptoms (LUTS) will relapse after discontinuing one medication from long-term combination therapy. METHODS: BPH/LUTS patients receiving initial AB +5ARI combination therapy for at least 1 year between January 2012 and January 2017 were retrospectively analyzed. The patients were classified into DC-AB group (n = 65, AB discontinued) and DC-5ARI group (n = 77, 5ARI discontinued) and followed up. Clinical effects were assessed at baseline and annually using the International Prostatic Symptoms Score (IPSS), quality of life (QoL) index, total prostate volume (TPV), maximal flow rate (Qmax), and prostate-specific antigen (PSA) level. RESULTS: Of total 1783 patients, 809 (45.4%) patients were identified with more than 1-year combination therapy. After withdrawal of one medication from combination therapy, the TPV progression (27.6% vs. - 10.8%; P < 0.001) and the requirement for prostate surgery (14.3% vs. 6.1%; P = 0.038) were significantly higher in the DC-5ARI group than in the DC-AB group. The rate of resuming combination therapy was significantly higher in the DC-5ARI group than in the DC-AB group (38.9% vs. 23.0%; P = 0.009). CONCLUSIONS: Adherence to combination BPH therapy is relatively low. Although patients adhered to combination therapy for more than 1 year, a higher risk of requiring prostate surgery or resuming combination therapy was observed in patients who discontinued 5ARI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Korea.
- Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Korea. bonanza96@eulji.ac.kr.
Zitieren
APA
Choi, J. D., Yoo, T. K., Kang, J. Y., Jung, H. D., & Lee, J. H. (2023). Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia. International Urology and Nephrology. https://doi.org/10.1007/s11255-023-03476-6
Vancouver
Choi JD, Yoo TK, Kang JY, Jung HD, Lee JH. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia. International Urology and Nephrology. 2023. doi:10.1007/s11255-023-03476-6
BibTeX
@article{Choi2023,
author = {Choi, Jae Duck and Yoo, Tag Keun and Kang, Jung Yoon and Jung, Hyuk-Dal and Lee, Jun Ho},
title = {Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia},
journal = {International Urology and Nephrology},
year = {2023},
doi = {10.1007/s11255-023-03476-6}
}
EUVIMED